drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
A bispecific T‑cell–engaging monoclonal antibody (REGN5458) that binds BCMA on plasma cells and CD3 on T cells to redirect cytotoxic T‑cell activity against BCMA-expressing plasma cells in MGUS/smoldering myeloma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Antibodies, Bispecific
drug_category
BISPECIFIC T ENGAGER
drug_class
Engager
drug_delivery_route
Intravenous
drug_mechanism_of_action
Linvoseltamab (REGN5458) is a bispecific monoclonal antibody that binds BCMA on plasma cells and CD3 on T cells, bringing T cells into close proximity to BCMA+ cells to form an immune synapse. This triggers TCR/CD3-mediated T‑cell activation, cytokine release, and perforin/granzyme‑mediated cytotoxicity, selectively lysing BCMA‑expressing plasma cells.
drug_name
Linvoseltamab
nct_id_drug_ref
NCT06140524